Such developments engaged only 5 laboratories (the U.S., Israel, Europe) in the world. The project is part of the strategy of development of the pharmaceutical industry of the Russian Federation for the period up to 2020. And by the end of this year, Russia will be such a unique laboratory.
Now the market share of domestic innovative drugs is less than 2 percent.
Because one of the priorities of the Strategy — stimulating the development and production of domestic innovative medicines, the formation of research centers and clusters to develop such drugs. The project budget is 550 million rubles.
The project is part of the strategy of development of the pharmaceutical industry of the Russian Federation for the period up to 2020.
There are two systemic problems of the Russian pharmaceutical industry.
The first — the inability of the market to provide the basic nomenclature of modern drugs, the whole cycle of production which would be on the territory of the Russian Federation.
The second — a low level of innovation and technology used in the development and manufacture of pharmaceuticals.
Created complex is able to solve them. All the research and production units will be in our country in the Republic of Tatarstan in the Technopolis "Khimgrad."
The technology — the creation of nanoparticles with desired properties on the basis of biodegradable biopolymers.
This implies innovation and development of the full production cycle — from substance to the formulation.
What will the implementation of the project?
First, by nanoscale drug delivery systems to provide improved 10 times higher bioavailability of highly active substances. This will be used in the form of tablets drugs that previously could only be administered by injection.
Second, on the shelves of pharmacies will be developed by Russian scientists hormonal drugs for the treatment of many women's diseases.
Thirdly, a new platform for creating modern anticancer drugs.
Fourth, the lab tech will match the best European standards.
Conclusion Complex at full capacity is expected in the first quarter of 2012.
For the record: In the next ten years, provided funding for the federal target program for the development of pharmaceutical medical industry in the amount of 188 billion rubles, of which 122.5 billion — the federal budget.
The purpose of the program — to reduce the gap between documentary, prospecting for and direct production and commercialization in the market.